focus -WSS

focus

author：leisure time 2025-09-06 01:57:27 - browse：58738

The FDA building -- First Opinion coverage from STAT — Adobe

The Food and Drug Administration on Thursday released a new accounting of artificial intelligence tools cleared for use in health care, adding scores of new products designed to reshape care in several areas of medicine.

The update included 171 new products that use artificial intelligence and machine learning, including 155 authorized since August of 2022. The agency’s data indicate that, after a lull during the Covid-19 pandemic, the number of authorized devices in 2023 is expected to increase by more than 30% over the prior year.

The list of AI devices was first published after a STAT investigation reported that the FDA had failed to keep the public informed on its regulation of AI devices, or crucial details on the tests undertaken to prove their safety and effectiveness. The summary documents that describe new AI devices often fail to break out the demographics of the patients they were tested on, or where the testing took place, which makes it difficult for clinicians and patients to understand their potential biases and weaknesses.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Skip the lead apron during X

WSS

Abbott's new heart device gets FDA advisory panel nod

Juul documents reveal insider tactics on political lobbying

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

Canadians with cystic fibrosis outlive Americans by a decade

Drug cartel violence flares in western Mexico after vigilante leader's killing

Juul documents reveal insider tactics on political lobbying

hotspot

focus

Wikipedia

Medicare details structure of new drug price negotiation program

Canadians with cystic fibrosis outlive Americans by a decade

Peter Hotez and the public health issue of online harassment

Readout Newsletter: Amylyx, Aurinia, and IQVIA

Activists slam private health insurers over coverage restrictions

AstraZeneca lung cancer study comes in below expectations

Wildfire smoke exposes gaps in outdoor worker protections

Crowdfunding for unproven stem cell procedures spreads misinformation

As demand for Covid shots wanes, Moderna seeks its next success

Dexcom's push to bring CGM to type 2 diabetes patients

entertainment

Long Covid research funding gets a major boost from NIH

Drug cartel violence flares in western Mexico after vigilante leader's killing

The biotech scorecard for Q3: 15 stock

Doctors on social media are being harassed and cyberbullied

A letter from the executive editor: The 2023 STATUS List

Lupron, used to halt puberty in children, may cause lasting health problems

leisure time

hotspot

knowledge

knowledge